Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamivudine for Mild Cognitive Impairment due to Alzheimer’s Disease
2024-514330-20-00Phase 2Completed
- Sponsor
- Fight AIDS and Infectious Diseases Foundation
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lamivudine in mild cognitive impairment due to Alzheimer's disease, sponsored by Fight AIDS and Infectious Diseases Foundation. Primary endpoints: Change in plasma neurodegeneration and amyloid biomarkers and Safety and tolerability. Started Jul 2024; status: completed.
02
Drugs
lamivudine
03
Conditions
mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on 2024-514330-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514330-20-00.